{"entity":{"id":"nct07153289","kind":"trial","name":"CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (ResCPa)","aka":["ResCPa"],"tldr":"A phase 1/2 trial in pancreatic cancer, run by University Hospital Tuebingen, not yet recruiting.","summary":"CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (ResCPa) is a phase 1/2, interventional study registered as NCT07153289 by University Hospital Tuebingen, with a registry enrolment figure of 38 participants, started 2026-07 and due to reach its primary completion in 2028-12. Interventions recorded: CD318-CAR-T cells. Conditions listed: Carcinoma, Pancreatic Ductal; Pancreatic Neoplasms. Primary outcome: Incidence and severity of dose-limiting toxicities (DLTs) and adverse events (AEs) after CD318-CAR-T cell infusion.. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07153289","url":"https://clinicaltrials.gov/study/NCT07153289"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":["car-t"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07153289","phase":"1/2","setting":"Response Features, Efficacy and Safety of CD318-targeted CAR-T Cell Therapy Against Pancreatic Cancer - ResCPa Study","sponsor":"University Hospital Tuebingen","enrolled":38,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07153289/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}